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In the previous issue of *Critical Care*, Ware and colleagues \[[@B1]\] showed that citrulline (CIT) plasma levels are extremely low in critically ill patients with sepsis and significantly lower in patients complicated with acute respiratory distress syndrome (ARDS). Thus, this study brings the new and important information that CIT depletion may be related to morbid events. In addition, these data form a strong rationale for CIT supplementation in intensive care unit (ICU) patients with sepsis.

For a long time, CIT was considered just a \'garbage\' amino acid because it is not included in proteins and is known only as an intermediary in the urea cycle. However, some early classic studies suggested that CIT had a unique metabolism and that its deficiency might be harmful (reviewed recently in \[[@B2]\]). The fact that CIT is almost absent from food (with the notable exception of watermelon) and is synthesized solely by the gut at the whole body level led Crenn and colleagues \[[@B3]\] to hypothesize, and then prove, that CIT plasma level is a reliable marker of intestinal functional mass. A number of studies worldwide confirmed the reliability of CIT as a biomarker of intestinal function in a number of pathological settings (reviewed recently in \[[@B4]\]).

CIT plasma levels appear to be extremely low in all patients. This contrasts with the results of other recent studies \[[@B5],[@B6]\] performed in critically ill patients in which CIT levels appear more variable at admission and in the course of the disease. The gut function was considered (existence of gut failure or not) in these two latter studies but was not considered in the article by Ware and colleagues \[[@B1]\], and so it is difficult to explain clearly where hypoCIT comes from. Surprisingly, the results show no difference between patients with renal failure and those without it. The same was observed in another study \[[@B7]\]. In the case of renal failure, CIT levels should be increased \[[@B8]\]. This indicates that an unknown covariable (for example, gut failure) tends to decrease CIT. Another point of complexity is the type of ICU patients. In the surgical ICU, in most cases, time 0 is the surgical operation. In the medical ICU (as in the present study), the time between acutization of the disease (for example, acute respiratory failure in chronic obstructive pulmonary disease) and admission in the ICU may range widely. Therefore, the metabolic status of patients may be widely variable from one to another, and this introduces a heterogeneity within the study and when comparing the results with those from similar work.

The authors hypothesize that CIT is overmetabolized, in particular in patients with ARDS, and they may be right, but alternatively we can hypothesize that low CIT is a result of an arginine (ARG) deficiency syndrome \[[@B9]\]. The authors claim that ARG levels (range of 9.6 to 40.0 μmol/L) were within the normal ranges, but it is unclear how these normal ranges were obtained. Normal ranges have been established on a similar Hitachi (Tokyo, Japan) analyzer \[[@B10]\] and are 80 ± 20 μmol/L (mean ± standard deviation). Other methods \[[@B11]\] provide similar normal values. Most patients in the article by Ware and colleagues appear, on the basis of this consensus, actually to be severely deficient in ARG, and, of course, this fact may radically change the interpretation of the data.

The problem of the ARG/CIT balance is a tricky one and falls into the category of the famous chicken-or-egg dilemma. For example, Ware and colleagues \[[@B1]\] present CIT as the substrate for nitric oxide synthase (NOS). This is right, but through recycling via argininosuccinate and ARG (reactions mediated by argininosuccinate synthase and lyase \[ASS + ASL\]). Hence, in the reaction mediated by NOS, ARG is the substrate and CIT is the product. Plenty of data give the ARG→CIT and the CIT→ARG fluxes at the whole body level \[[@B12]\] or at the organ level by using stable isotopes and arterio-venous differences. I do not know of any data that establish, at the cellular level, that ARG is a better precursor of nitric oxide (NO) than CIT or vice versa. In addition, *in vitro*data suggest that the ability of ARG or CIT to generate NO in macrophages (which play a key role in sepsis and ARDS) is co-regulated by glutamine \[[@B13]\], whose availability is decreased in sepsis. In the case of sepsis, we cannot safely speculate, because, on the one hand, it is true that ASS + ASL and NOS channel CIT, but on the other hand, the ARG transporter CAT2 (cationic amino acid transporter 2) is also connected to inducible NOS, and both are overexpressed in sepsis \[[@B14]\]. The absence of any difference in ARG levels between patients with ARDS and those without it apparently supports the authors\' view that the key is CIT, not ARG. However, the absence of any correlation between amino acids and NO end-products (that is, nitrate + nitrate) supports the idea that the answer is in the lung, not in the plasma, and that - in the absence of measurements with stable isotopes, arterio-venous difference, and measurements in the bronchoalveolar fluid - all these considerations are just a matter of speculation. As all these determinations are invasive and not necessary feasible in the ICU, I suggest two avenues of research in order to progress in this field. The first one is mechanistic and uses an experimental model of sepsis with ARDS. The second is pragmatic: as suggested by Ware and colleagues \[[@B1]\], it is to supplement patients with CIT at admission in the ICU and look at ARDS behavior.

In conclusion, we must avoid overspeculating from these results, but the great merit of Ware and colleagues \[[@B1]\] is to establish, on the basis of a large number of ICU patients, that plasma CIT level measured at admission may be a biomarker of ARDS. In addition, the results of this study, in conjunction with those of three recent experimental studies in sepsis conditions \[[@B15]-[@B17]\], offer a strong rationale for an interventional study in ICU patients.
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